Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AorticLab logo — High-tech cutting-edge solutions in the treatment of severe...

AorticLab

High-tech cutting-edge solutions in the treatment of severe AORTIC STENOSIS

Founded 2016 Italy Italy 23 employees Debt Financing Total: $4.20M Medical Devices

General Information

Company Name AorticLab
Founded Year 2016
Location Italy Italy
Founders / Decision Makers
Team member
Employees 23
Industries Medical Devices
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with AorticLab. To contact AorticLab, visit aorticlab.ch.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AorticLab compare?

A PDF of AorticLab and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AorticLab soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AorticLab

AorticLab is a high-tech startup that focuses on providing advanced solutions for the treatment of severe AORTIC STENOSIS. The company's mission is to address the needs of patients suffering from this condition, offering hope to those who previously had limited treatment options due to age or health constraints. AorticLab aims to advance the standards of aortic stenosis treatment by enabling safer TAVI procedures, minimizing the risks of cerebral and peripheral complications. The company's dedication to improving patients' quality of life is evident in its innovative product development. AorticLab is currently developing FLOwer, an Embolic Protection Device, and GEMINI, a Transcatheter Treatment, both of which offer promising solutions for the effective and less invasive treatment of aortic stenosis. With a foundation built on extensive experience and a passionate, pioneering approach, AorticLab is poised to make a significant impact in the field of cardiovascular health. As of September 20, 2021, AorticLab secured a €1.50M Debt Financing investment from UniCredit, bolstering its endeavors to bring its products to market. The company's headquarters are situated in Italy, and it is set to release FLOwer commercially in 2023 in selected European countries. AorticLab's commitment to innovation and patient safety positions it as a promising venture for potential investors seeking to contribute to the advancement of cardiovascular care and medical technology.

Business keywords: Aortic Stenosis, Cardiovascular, Medical Device, Transcatheter Treatment, Aortic Valve, TAVI, TAVR, Embolic Protection Device

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing €1.50M 1
UniCredit
UniCredit
20 Sep 2021
Venture Round €1.40M -
27 May 2021
Equity Crowdfunding €1.30M 3
Club degli Investitori Italian Angels for Growth Doorway
Club degli Investitori, Italian Angels for Growth +1
30 Jul 2020

AorticLab Alternatives & Competitors

View All Alternatives
AorticLab vs
JenaValve Technology, Inc.
JenaValve Technology, Inc. United States

Aortic regurgitation is different. So is our valve.

Series C
149 employees
Health Care, Manufacturing
Compare AorticLab vs JenaValve Technology, Inc.
AorticLab vs
Transverse Medical Inc
Transverse Medical Inc United States

Point-Guard Protected™ Stroke Matters. Safeguard the Brain, Treat the Heart.

Venture round
10 employees
Biotechnology, Health Care
AorticLab vs
Emboline, Inc.
Emboline, Inc. United States

The Emboliner® Embolic Protection Catheter protects the brain and body from stroke-producing debris...

Series D
21 employees
Health Care, Medical Devices
View all alternatives

FAQ About AorticLab

High-tech cutting-edge solutions in the treatment of severe AORTIC STENOSIS
AorticLab was founded in 2016.
AorticLab is headquartered in Italy.
AorticLab operates in Medical Devices. Its work centres on Aortic Stenosis, Cardiovascular, Medical Device and Transcatheter Treatment.
AorticLab has approximately 23 employees.
AorticLab has completed 3 funding rounds, raising a total of $4.20M. The latest funding stage is Debt Financing.
Top alternatives and competitors to AorticLab include JenaValve Technology, Inc., Transverse Medical Inc, Emboline, Inc., Claret Medical, Pi-Cardia. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AorticLab and JenaValve Technology, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AorticLab, https://bouncewatch.com/company/aorticlab, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout